Читать книгу Biopharmaceutics - Группа авторов - Страница 3

1 Chapter 3Table 3.1 Solubility criteria as listed in the BP and USP.

2 Chapter 4Table 4.1 Impact of dose and permeability on the target solubility for a candidat...Table 4.2 An overview of the four levels of biorelevant media that can simulate t...Table 4.3 Composition of commonly used simulated intestinal media: fasted state s...

3 Chapter 5Table 5.1 Human intestinal transporters shown to be involved in the transport of ...

4 Chapter 6Table 6.1 Example experimental setup within USP3 apparatus to mimic fasted state.Table 6.2 Overview of USP dissolution apparatus (ER = extended release; IR = imme...Table 6.3 Summary of USP compendial dissolution media.Table 6.4 Composition and physicochemical characteristics of FaSSGF.Table 6.5 Composition and physicochemical characteristics of three versions of F...Table 6.6 Composition and physicochemical characteristics of FeSSGF.Table 6.7 Composition and physicochemical characteristics of FeSSIF media publis...Table 6.8 Composition and physicochemical characteristics of simulated colonic f...

5 Chapter 7Table 7.1 Summary of oral drug product design considerations during early develo...Table 7.2 Summary of the enabling technologies that can be applied to a compound...

6 Chapter 8Table 8.1 Biopharmaceutics parameters and their cut‐off values guiding the devel...Table 8.2 Formulation strategies to improve oral drug absorption.

7 Chapter 10Table 10.1 Potential relationships between dissolution and clinical performance, ...

8 Chapter 11Table 11.1 The relative anatomical lengths and surface areas of various regions ...Table 11.2 Gastric fluid volumes reported in healthy subjects as determined by m...

9 Chapter 12Table 12.1 Summary of key parameters within the DLM and the equations that relat...

10 Chapter 13Table 13.1 Physiological changes during pregnancy and its effects on drug perfor...Table 13.2 Diabetes‐mellitus‐induced physiological, motor and sensory alteration...

11 Chapter 15Table 15.1 Typical characteristics of common parenteral injection types.Table 15.2 IM and SC injection volumes in preclinical species.Table 15.3 Composition of ISF.

12 Chapter 17Table 17.1 Changes in pharmacokinetics mediated by gut microbiota with clinical ...